Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$16.04 USD
-0.08 (-0.50%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $16.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Roivant Sciences Ltd. has a market cap of $11.01B, which represents its share price of $16.12 multiplied by its outstanding shares number of 682.88M. As a large-cap company, ROIV's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ROIV 16.04 -0.08(-0.50%)
Will ROIV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice
Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Other News for ROIV
Is ROIV showing downside potential? MACD Bearish Signal Line Cross shows up after sinking 0.5%
ROIV rises 0.56% on October 9, leaving the technical picture intact
ROIV falls 0.56% on October 8, leaving the technical picture intact
Slingshot Bullish appears for ROIV after 0.86% move
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)